Bringing the Oncology Community Together

Personalized Medicine: A Promising Future in Oncology Practice

Andre Goy, MD, MS
Published Online: Tuesday, April 10, 2012
Andre Goy, MD, MS

Andre Goy, MD, MS

Editor-in-Chief
Contemporary Oncology

Chief, Lymphoma Division, Chairman

John Theurer Cancer Center at Hackensack University Medical Center

This issue of Contemporary Oncology includes a focus on 2 challenging situations: management of metastatic triple negative breast cancer (TNBC) and of advanced stage non–small–cell lung cancer (NSCLC).

Christiansen and colleagues report on actual first-line treatment patterns for the management of metastatic TNBC in community practice settings in the United States. TNBC is characterized by aggressive tumors with cells that lack estrogen receptors (ERs) and progesterone receptors (PRs), and do not overexpress HER2. The study looked at patients with stage IV metastatic TNBC in 2 databases (Georgia Cancer Specialists Database and International Oncology Network’s Treatment and Outcomes Database). Though the number of patients evaluated was relatively small, the patterns seen confirmed previous observations.That is, the analysis found that there was no general consensus in current treatment for stage IV TNBC. The basis of therapy remains the use of conventional cytotoxics from single agent chemotherapy (capecitabine, taxanes) or combinations regimens (cyclophosphamide, doxorubicin with and without bevacizumab), with corresponding significant differences in costs.

Although the metastatic potential in TNBC is similar to that of other breast cancer subtypes, these tumors are associated with a shorter median time to relapse, a greater chance of visceral- and organ-based metastatic disease, and overall worse outcomes and survival. Unfortunately, there are no reliable prognostic factors in TNBC, and molecular studies have shown this is a very heterogeneous disease.

Although TNBC is often referred to as surrogate for basal-like breast cancer, there is clearly a need for further subclassification. One of the main issues, as seen in these results, is the lack of clear guidelines in TNBC. Ongoing studies (more than 60 currently) looking at new combinations—including new targeted therapies focusing on EGFR, CHK-1, PARP-1, PI3K/mTOR inhibitor, and TKI (dasatinib), among others—may shed some light on the management of this disease. Recent work (Lehmann, BD et al. J Clin Invest. 2011;121:2750-2767.) identified 6 molecular subtypes of TNBC. Using representative TNBC cell lines of the 6 distinct subtypes, investigators showed that the various subtypes had different sensitivities to targeted therapies currently under laboratory and clinical investigation, providing a rationale for future studies.

Meanwhile, the treatment of NSCLC has seen a paradigm shift over the last decade, with the integration of novel therapies based on a better understanding of some of the driving mutations. In this issue, the article by Steven A. Sandler, MD, reviews these advances.

NSCLC, which accounts for approximately 85% of all lung cancers, is divided further into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma histologies. Lung cancer is the leading cause of cancer-related mortality in men and women, both in the United States and worldwide. In 2006, lung cancer resulted in 158,000 deaths in the United States alone—more than colorectal, breast, and prostate cancer combined.

Most lung carcinomas are diagnosed at an advanced stage, conferring a poor prognosis. Only a third of patients with NSCLC present at diagnosis with disease that is sufficiently localized to attempt curative surgical resection (stages IA and IB, IIA and IIB, and IIIA). Radiation is a reasonable option for lung cancer treatment for those who are not candidates for surgery. However, approximately half of patients who undergo an attempt at curative local therapy experience local or systemic relapse. As a result, about 80% of all patients with NSCLC receive chemotherapy at some point during the course of their disease. NSCLC is only moderately sensitive to chemotherapy, with single-agent response rates in the range of 15% or better. Newer agents (eg, gemcitabine, pemetrexed, docetaxel, vinorelbine) have shown promising single-agent activity, with response rates from 20% to 25% (although there has been no clear benefit demonstrated with triple agents combinations).

Page: 12Next Page (2) >>
Call for Papers
Related Articles
Pancoast Tumors of the Lung: Improved Results
Every patient with a pancoast tumor of the lung should be evaluated by a Pancoast-experienced thoracic surgeon (and neurosurgeon) before ruling out surgery, and before starting induction therapy.
Phase III Clinical Trials in HER2-Positive Breast Cancer
Expert panelists explore several large clinical trials examining therapies for patients with HER2-positive breast cancer that are currently ongoing or have recently completed.
Next-Generation Targeted Therapies in NSCLC
In this segment, panelists discuss the number of early-phase clinical trials that have demonstrated impressive efficacy for next-generation ALK and EGFR inhibitors for patients with non-small cell lung cancer.
Experts Support Broader Pertuzumab Use in HER2-Positive Breast Cancer
The recent approval of pertuzumab as part of a combination neoadjuvant treatment for patients with early-stage breast cancer has paved the way for wider use of the regimen in preoperative settings.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.